
Q3 2025: 10 FDA Decisions to Watch in the Realm of Oncology
As the second quarter of 2025 closes, the pace of oncology innovation shows no signs of slowing. Recent FDA approvals have reinforced the shift toward more targeted, immunologically driven, and personalized therapies across a broad spectrum of cancers. …